Effects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic Syndrome, Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), American College of Cardiology Foundation, Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation, Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel, Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women, Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial, LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—implications for LDL management, The metabolic syndrome: targeting dyslipidemia to reduce coronary risk, Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study, A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study, Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy, Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial, Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice, Physiological role and clinical relevance of high-density lipoprotein subclasses, Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin, Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non–high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy II) trial, Incremental Risk of Developing Severe COVID-19 Among Mexican Patients With Diabetes Attributed to Social and Health Care Access Disadvantages, A Randomized Controlled Trial to Evaluate the Effects of a Smartphone Application-Based Lifestyle Coaching Program on Gestational Weight Gain, Glycemic Control, Maternal, and Neonatal Outcomes in Women With Gestational Diabetes Mellitus: The SMART-GDM Study, Glucose-Dependent Insulinotropic Peptide in the High-Normal Range Is Associated With Increased Carotid Intima-Media Thickness, Antidiabetes Agents and Incident Depression: A Nationwide Population-Based Study, Sex Differences in Rates of Change and Burden of Metabolic Risk Factors Among Adults Who Did and Did Not Go On to Develop Diabetes: Two Decades of Follow-up From the Tehran Lipid and Glucose Study, Relative Risk of Cardiovascular Disease Is Higher in Women With Type 2 Diabetes, but Not in Those With Prediabetes, as Compared With Men, Institutional Subscriptions and Site Licenses, Special Podcast Series: Therapeutic Inertia, Special Podcast Series: Influenza Podcasts, http://creativecommons.org/licenses/by-nc-nd/3.0/. Second, patients in the RSV20 group included both those treated previously with RSV10 and those given placebo previously, possibly leading to heterogeneity in clinical response. The study population included men and women, aged ≥18 years, with the metabolic syndrome as defined by ATP III criteria (1) (Table 1). They include atorvastatin (Lipitor), rosuvastatin (Crestor), and other generic and brand-name versions. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. Study procedures were approved by ethics committees, and all patients provided informed, written consent. © 2020 American College of Cardiology Foundation. METHODS: After a 6-week dietary run-in, patients aged > or = 18 years with type 2 diabetes and LDL-C > or = 3.3 mmol/L were randomised to double … Congenital Heart Disease and Pediatric Cardiology, Invasive Cardiovascular Angiography and Intervention, Pulmonary Hypertension and Venous Thromboembolism, CardioSource Plus for Institutions and Practices, Nuclear Cardiology and Cardiac CT Meeting on Demand, Annual Scientific Session and Related Events, ACC Quality Improvement for Institutions Program, National Cardiovascular Data Registry (NCDR), CardioSmart for Your Patients: About Type 2 Diabetes, Congenital Heart Disease and     Pediatric Cardiology, Invasive Cardiovascular Angiography    and Intervention, Pulmonary Hypertension and Venous     Thromboembolism. After the 8-week treatment, percentage change (least-square means ± standard error) in the apoB/A1 ratio in the rosuvastatin/ezetimibe group was significantly decreased compared to the rosuvastatin group (− 46.14 ± 1.58% vs. − 41.30 ± 1.58%, respectively; P = 0.03).